Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;43(11):1368-1373.
doi: 10.1038/s41372-023-01751-z. Epub 2023 Aug 18.

Serum ferritin values in neonates <29 weeks' gestation are highly variable and do not correlate with reticulocyte hemoglobin content

Collaborators, Affiliations

Serum ferritin values in neonates <29 weeks' gestation are highly variable and do not correlate with reticulocyte hemoglobin content

Timothy M Bahr et al. J Perinatol. 2023 Nov.

Abstract

Objectives: To compare serum ferritin and RET-He values among extremely low gestational age neonates ELGANs with other markers of iron-deficient erythropoiesis.

Study design: This is a secondary analysis of the NICHD Darbepoetin Trial. Study data from placebo recipients who had a serum ferritin, a RET-He, and a mean corpuscular volume (MCV) measurement within a 24-hour period were analyzed for correlation.

Results: Mixed linear regression models showed no association between ferritin and RET-He at both early (β = 0.0016, p = 0.40) and late (β = -0.0001, p = 0.96) time points. Positive associations were observed between RET-He and MCV at baseline, early, and late time points (p < 0.01, =0.01, <0.001, respectively), while ferritin was not associated with MCV at any time point.

Conclusions: Our study shows that RET-He is better correlated with MCV as a marker of iron-limited erythropoiesis than ferritin. The results suggest that ferritin is limited as a marker of iron sufficiency in premature infants.

Study identification: FDA IND Number 100138; ClinicalTrials.gov number NCT03169881; NRN ID number NICHD-NRN-0058 (Darbe).

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no conflicts of interest relevant to this article to disclose.

Figures

Figure 1.
Figure 1.
Scatter plots showing the relationship between simultaneous obtained RET-He and serum ferritin concentration measurements in neonates born at less than 29 weeks gestation who did not receive darbepoetin alpha. A regression line is drawn for on each plot. (A) Paired values obtained at or before 27 days of life (r=−0.24, β=0.0016, p=0.41); (B) paired values obtained on or after 28 days of life (r=−0.16, β=−0.0001, p=0.96).
Figure 2.
Figure 2.
Scatter plots showing the relationship between simultaneous obtained RET-He and MCV, a red blood cell index where low values are associated with iron-limited erythropoiesis. (A) RET-He vs. MCV at enrollment (<24 hours of life; r=0.25, β=0.14, p<0.01); (B) RET-He vs. MCV at 11-17 days of life (r=0.32, β=0.12, p=0.01). (C) RET-He vs. MCV at 38-45 days of life (r=0.39, β=0.17, p<0.01).
Figure 3.
Figure 3.
Scatter plots showing the relationship between simultaneous obtained serum ferritin concentration and MCV, a red blood cell index where low values are associated with iron-limited erythropoiesis. (A) serum ferritin concentration vs. MCV at 11-17 days of life (r=−0.25, β=−6.49, p=0.01). (B) serum ferritin concentration vs. MCV at 38-45 days of life (r=−0.55, β=−12.8, p<0.01).
Figure 4.
Figure 4.
Scatter plots showing the relationship between cumulative iron dose administered (mg/kg) and (A) RET-He in the first 27 days of life (r=0.32, β=0.12, p<0.01) or (B) serum ferritin concentrations in the first 27 days of life (r=−0.67, β=−0.95, p<0.001). The cumulative iron dose plotted is the cumulative iron dose administered from birth through the day the laboratory value (RET-He or serum ferritin) was obtained.

References

    1. Kling PJ. Iron Nutrition, Erythrocytes, and Erythropoietin in the NICU: Erythropoietic and Neuroprotective Effects. NeoReviews 2020;21:e80–8. 10.1542/neo.21-2-e80. - DOI - PubMed
    1. Cusick S, Georgieff M, Rao R. Approaches for Reducing the Risk of Early-Life Iron Deficiency-Induced Brain Dysfunction in Children. Nutrients 2018;10:227. 10.3390/nu10020227. - DOI - PMC - PubMed
    1. Geng F, Mai X, Zhan J, Xu L, Zhao Z, Georgieff M, et al. Impact of Fetal-Neonatal Iron Deficiency on Recognition Memory at 2 Months of Age. J Pediatr 2015;167:1226–32. 10.1016/j.jpeds.2015.08.035. - DOI - PMC - PubMed
    1. Armony-Sivan R, Eidelman AI, Lanir A, Sredni D, Yehuda S. Iron status and neurobehavioral development of premature infants. J Perinatol Off J Calif Perinat Assoc 2004;24:757–62. 10.1038/sj.jp.7211178. - DOI - PubMed
    1. Amin SB, Orlando M, Wang H. Latent iron deficiency in utero is associated with abnormal auditory neural myelination in ≥ 35 weeks gestational age infants. J Pediatr 2013;163:1267–71. 10.1016/j.jpeds.2013.06.020. - DOI - PubMed

Publication types

Associated data